Jagsonpal Pharmaceuticals share news, announcements and annual reports
NSE: JAGSNPHARMBSE: 507789Pharmaceuticals & BiotechnologySmall Cap
Jagsonpal Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1987 on BSE, Mar 2000 on NSE
Last close ₹221.94down ₹9.02 (3.91%)BSE ₹221.45
Share price at the NSE close on 29 Oct 2026. Previous close ₹230.96.
29 Oct: open ₹219.52, high ₹231.81, low ₹211.00
52-week range of traded prices to 29 Oct 2026
₹155.00Low, 22 Jan 2026₹264.50High, 30 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,466 Cr1,360th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 32.23
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 6.09
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.80%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,49,04126.1% delivered
Jagsonpal Pharmaceuticals disputes and clarifications
30 filed, newest first.
Mar 2026
Dec 2025
30 Dec · Legal
Apr 2025
28 Apr · Legal
The exchange asked on 25 Apr 2025
2 Apr · Legal
Feb 2025
21 Feb · Legal
Oct 2024
Sep 2023
13 Sep · Legal
The exchange asked on 12 Sep 2023
Sep 2022
15 Sep · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited with respect to announcement dated 15-Sep-2022 informing about Annual General Meeting.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Brief details of items deliberated and results thereof; The response of the company is awaited.
Aug 2022
10 Aug · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited with respect to announcement dated 16-Jul-2022 informing about Appointment of Statutory Auditor.On the basis of aforesaid announcement, the Company is required to provide/clarify the following:Change in directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), Auditor and Compliance Officer: 1. Brief profile (in case of appointment) The response of the company is awaited.
Feb 2022
28 Feb · Legal
The exchange asked on 25 Feb 2022
Dec 2021
29 Dec · Legal
The exchange asked on 28 Dec 2021
Jul 2021
12 Jul · Legal
The exchange asked on 9 Jul 2021
Jun 2021
9 Jun · Legal
The exchange asked on 4 Jun 2021
Apr 2021
29 Apr · Legal
The exchange asked on 23 Apr 2021
Nov 2020
19 Nov · Legal
The exchange asked on 18 Nov 2020
Aug 2020
3 Aug · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Statement of Cash Flow not submitted -2. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.3 Aug · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited for the quarter ended 30-Jun-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Jun 2020
24 Jun · Legal
The exchange asked on 23 Jun 2020
Apr 2020
10 Apr · Legal
The exchange asked on 9 Apr 2020
Nov 2019
15 Nov · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited with respect to announcement dated 14-Nov-2019, regarding Board meeting held on November 14, 2019. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment). The response of the Company is awaited.
Sep 2019
Aug 2019
19 Aug · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Jun 2018
1 Jun · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Apr 2014
28 Apr · Legal
Price movement : Significant price movement has been observed in Jagsonpal Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Jagsonpal Pharmaceuticals Limited has vide its letter inter-alia stated,"In compliance to above we hereby confirm that NO NON Compliance / violation is from company's part. Why there is so fluctuation in share prices we don't have any information and nothing unusal / important activity has been conducted by the company."